Icon

NORTHERA (nda203202)- (100MG,200MG,300MG)

DROXIDOPA LUNDBECK NA LTD
100MG,200MG,300MG
No No
Expired 2019-Feb-18
2021-Feb-18 None
None No
NORTHERA is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
14 0 14
Total Other Developers 10
Drugs with Suitability No
100MG ** ** - 1 10
200MG ** ** - - 11
300MG ** ** - 9 1
NDA Sales Available Total Generic Sales Available
Yes 12
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****** ***** ******* *********** ****-*, **** **. ***, ***, ****** - **, ******* ******** ****, *****, ******, *********** ******, ***** (***) ***
****** ****** ****** ****** ******* ******* *********** ****** **. ***, ******* *******, *********** ******,, **********, ********* ******, ***** (***) ***
****** *** ****** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** *** ****** *** *** *************** *** *********** **, **** ****, **********, *** ****** (**) *****, ****** ****** (***) ***
****** ***** ****** ***** ************ ******* *********** **** **. *-*/*&* *******, (******* ******** ****) ******, ******* ***** *.*. **. **, ***-******, ****-*********, *********, ******* ******, ***** (***) ***
****** ***** ****-**** ******** ***. *********** **** ****** ****, ********, **** (**) *****, ****** ****** (***) ***
****** ********** ***** ****** *** *********** *** *** *** ********* ** ***** *, *, *-* & *, **********, *** ****** (**) *****-****, ****** ****** (***) ***
****** ***** **** *** ***** ************ ******* *********** ****** ** ****, ****, ****, **** ******* *****, ****** ********, *****, ******** ******* ******, ***** (***) ***
****** ******* ****** *** ******* ***************, ***. *********** ** ***** *****, *********, *** **** (**) *****-****, ****** ****** (***) ***
****** *** ***** *** ************** ********** ******* *********** **** **. *-**, ********** **** *****-**** *, *.*.*. *****, ******, ****** ******, ***** (***) ***
****** ********* ****** *** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***
****** ****** ****** *** ****** ****** ******* *********** *-*\*\*, **** ****, *******, *********** *************, *********** ******, ***** (***) ***
****** ******** ******* *** ********* ************** ******* ******* *********** ***** **. ***/*** *** ****/***/*, **** **, ****** ****, (** *) ******* *****, *********** *****, *********, ** ******, ***** (***) ***
****** ***** ******* ****** ******* *********** **** **. **-**, ****** **, ******** ****, *********, ****** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.